ABBV250110C180000
- 0.27
- -0.95-77.87%
AbbVie Newsroom
Assessing AbbVie: Insights From 17 Financial Analysts
8 Health Care Stocks Whale Activity In Today's Session
Resilience Partners With Parvus Therapeutics for Development and Manufacturing of PVT401, a Novel Autoimmune Drug Candidate for IBD
AbbVie Price Target Cut to $211.00/Share From $215.00 by Truist Securities
AbbVie Is Maintained at Buy by Truist Securities
AbbVie Analyst Ratings
Truist Financial Maintains AbbVie(ABBV.US) With Buy Rating, Announces Target Price $211
AbbVie (ABBV) Stock Moves -0.32%: What You Should Know
Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?
Sector Update: Health Care Stocks Mixed Premarket Tuesday
Express News | Refile-Buzz-Obesity Drugs, M&a Among Key Pharma Drivers for 2025, Berenberg Says
Express News | Capsida - Eligible for Additional Milestones and Royalties
Express News | Capsida - Co to Receive $40 Million License Payment
Express News | Capsida Announces Abbvie Opt-in for First Genetic Medicine Program From Neurodegenerative Disease Collaboration
Capsida Announces AbbVie Opt-in for First Genetic Medicine Program From Neurodegenerative Disease Collaboration
AbbVie Lowers Q4 and Full-Year Earnings Outlook on $1.6 Billion Acquired IPR&D and Milestones Expense
CoolMonth Is Back With Deals on CoolSculpting Elite by Allergan Aesthetics
AbbVie (ABBV.US) lowers annual profit forecast, falling short of market expectations.
The USA biotechnology company AbbVie (ABBV.US) has revised down its adjusted earnings per share forecast for the fiscal year 2024, from the original $10.90 to $10.94 to a range of $10.02 to $10.06, which is below the market average expectation of $10.94, due to milestone payments and research and development costs reaching $1.6 billion. AbbVie expects adjusted earnings per share for the fourth quarter to be between $2.06 and $2.10, compared to $2.79 in the same period last year, and the company plans to announce its fourth quarter results on January 31.
AbbVie Announced Q4 2024 Earnings To Include $1.6B Acquired IPR&D Costs, Impacting EPS By $0.88; Final Results Pending; Q4 Adj EPS $2.06-$2.10; FY24 Adj EPS Guidance $10.02-$10.06
Express News | Abbvie Inc Q4 Shr View $2.98 -- LSEG IBES Data